Thursday, July 09, 2026
.jpg)
Chennai-based Iswarya Fertility Center (Iswarya), one of India's largest and fastest-growing fertility care providers, today announced a growth investment of more than INR 350 crore (approximately US$37 million) from OrbiMed Asia (OrbiMed), a leading global healthcare investment firm. 
Chennai, India | 9 July 2026: Chennai-based Iswarya Fertility Center (Iswarya), one of India's largest and fastest-growing fertility care providers, today announced a growth investment of more than INR 350 crore (approximately US$37 million) from OrbiMed Asia (OrbiMed), a leading global healthcare investment firm. The investment marks a significant milestone in Iswarya’s mission to expand the reach of fertility care across India and help address the country’s declining birth rates.
Established in 1986, Iswarya has evolved into South India’s largest fertility network with 85+ centers across eight states, serving more than 300,000 couples over four decades. Today, the company is led by Managing Director Dr. Arun Muthuvel, who is spearheading its growth, and offers services spanning from IVF, IUI, fertility preservation, genetics, and advanced reproductive treatments.
The investment will enable Iswarya to establish new centers in existing and underserved markets, strengthen clinical infrastructure, invest in digital capabilities and expand its embryology talent pipeline.
Commenting on the investment, Dr. Arun Muthuvel, Managing Director, Iswarya Fertility Center, said:
" For nearly four decades, Iswarya has been driven by a single purpose — making parenthood possible. Our focus over the next phase is clear: deepen our pan-India presence, enter underserved geographies and keep raising the bar on clinical outcomes. We will invest in our people, technology and patient experience, ensuring that excellence remains at the heart of everything we do. We are delighted to welcome OrbiMed as our partner on this journey. Their global healthcare expertise and shared commitment to clinical excellence make them an ideal partner as we expand access to high-quality fertility care across India and, over time, into international markets.”
Dr. S. Chandralekha, Founder and Chief Clinical Officer, Iswarya Fertility Center, said:
"When we started Iswarya in 1986, IVF was beyond the reach of most Indian families. From the very beginning, every center we have opened has been guided by a simple belief: clinical excellence and compassion must always go hand in hand. As we enter our next phase of growth, that purpose remains unchanged. Our commitment to clinical rigour, ethical practice, and placing patients at the center of every decision continues to define who we are. Guided by these values, we will continue our mission of making world-class fertility care more accessible, helping many more families experience the joy of parenting, and building a future where hope is transformed into new beginnings for generations to come.”
Dr. Sunny Sharma, Partner and Senior Managing Director, and Arun Sadhanandham, Managing Director at OrbiMed, said in a joint statement:
“Iswarya has established itself as one of the country’s leading fertility platforms through its strong clinical outcomes, trusted brand, capital-efficient operating model, and experienced leadership team. We are delighted to partner with Dr. Arun, Dr. Chandralekha, and the entire management team as they continue to build a category-defining fertility care platform.”
Veda Corporate Advisors were the Financial Advisors to the Company and its promoters.
Commenting on the transaction, VP Rajan, Managing Director, Veda Corporate Advisors, said:
“Iswarya represents a rare combination of clinical depth, brand trust, and disciplined execution. The transaction drew strong interest from marquee investors, and we are delighted to have advised the promoters on this landmark deal for India’s fertility sector.”
India’s total fertility rate has fallen below replacement levels, while infertility affects a growing number of couples due to delayed parenthood, lifestyle factors and rising diagnosis rates. Despite this, fertility treatment penetration in India remains among the lowest globally — meaning millions of couples who could benefit from IVF are yet to access it. Expanding the availability of quality fertility care is therefore both a meaningful healthcare need and a national demographic priority.
Iswarya differentiates itself through a patient-centric, technology-enabled approach, a hub-and-spoke operating model and a strong digital-led consumer brand, while maintaining industry-leading profitability.
Looking ahead, Iswarya will deepen its presence in existing markets, enter underserved geographies and continue investing in clinical excellence, medical education and innovation.
.jpeg)
.jpg)
.jpg)
.jpg)
.jpg)
.jpg)
.jpg)
.jpg)
.jpeg)
